Table II.

T-cell therapy for CMV infection/reactivation after stem cell transplant.

Reference	n	HSCT type	Strategy	End points	Results
Cobbold, 2005 (9)	9	MRD, MUD	Pre-emptive therapy	Safety Efficacy CTL persistence	➢2 cases of GvHD aggravation after CTL ➢8/9 patients cleared CMV ➢Detectable CMV-specific T cells in all patients
Leen, 2006 (11) and Hanley 2013(15)	34	MRD, MUD, haplo	Prophylaxis	Safety Efficacy CTL expansion	➢No GvHD ➢8/11 patients with CMV cleared the virus within 7 d ➢Up to 5-fold increase in CMV-specific T cells
Peggs, 2011 (10)	18	MRD, MUD	Prophylaxis Pre-emptive therapy	Safety Efficacy CTL expansion	➢3 cases grade II-III acute GvHD ➢5 cases extensive chronic GvHD ➢6/7 patients CMV-free ➢9/11 patients treated pre-emptively had no CMV reactivation ➢Detectable CMV-CTL in all patients
Hanley, 2012 (51)	7	Cord blood	Prophylaxis treatment	Safety Efficacy CTL expansion	➢No de novo GvHD ➢6 patients remained CMV-free ➢1 patient had CMV not requiring additional therapy ➢CTL detected >1 y after infusion
Blyth, 2013 (49)	50	MRD, MUD	Prophylaxis	Safety Efficacy	➢Same rate of GvHD as controls ➢46% CMV reactivation versus 60% in control cohort